Fecha de publicación: -- Fuente: Labiotech Lugar: In Depth There is a lot going on in the GLP-1 space, a market that landed $79 billion last year, and could shift significantly in the coming years.
The post Beyond Ozempic: the GLP-1 landscape in 2026  appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.